Is it Wise to Hold Teleflex (TFX) Stock in Your Portfolio Now?

Hims & Hers Health's earnings are expected to surge 272.7% in 2024 compared with the industry's 16.6%. HIMS' earnings surpassed estimates in three of the trailing four quarters and missed in one, delivering an average surprise of 79.2%. Its shares have surged 136.4% against the industry's 28% decline in the past year. HIMS sports a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today's Zacks #1 Rank stocks here. Medpace, carrying a Zacks Rank #2 (Buy) at present, has an estimated 20 ...